Juvenile Paget’s disease with compound heterozygous mutations in TNFRSF11B presenting with recurrent clavicular fractures and a mild skeletal phenotype by Naot, Dorit et al.
Journal Pre-proof
Juvenile Paget’s disease with compound heterozygous mutations in
TNFRSF11B presenting with recurrent clavicular fractures and a mild
skeletal phenotype
Dorit Naot, Louise C. Wilson, Jeremy Allgrove, Eleanor Adviento,





Received Date: 27 May 2019
Revised Date: 19 September 2019
Accepted Date: 2 October 2019
Please cite this article as: Naot D, Wilson LC, Allgrove J, Adviento E, Piec I, Musson DS,
Cundy T, Calder AD, Juvenile Paget’s disease with compound heterozygous mutations in
TNFRSF11B presenting with recurrent clavicular fractures and a mild skeletal phenotype,
Bone (2019), doi: https://doi.org/10.1016/j.bone.2019.115098
This is a PDF file of an article that has undergone enhancements after acceptance, such as
the addition of a cover page and metadata, and formatting for readability, but it is not yet the
definitive version of record. This version will undergo additional copyediting, typesetting and
review before it is published in its final form, but we are providing this version to give early
visibility of the article. Please note that, during the production process, errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal
pertain.
© 2019 Published by Elsevier.
1 
 
Juvenile Paget’s disease with compound heterozygous mutations in 
TNFRSF11B presenting with recurrent clavicular fractures and a mild 
skeletal phenotype 
 
Dorit Naot a (d.naot@auckland.ac.nz) 
Louise C Wilson b (Louise.Wilson@gosh.nhs.uk) 
Jeremy Allgrove b (jeremy.allgrove@nhs.net) 
Eleanor Adviento a (e.adviento@auckland.ac.nz) 
Isabelle Piecc (I.Piec@uea.ac.uk) 
David S Musson a (d.musson@auckland.ac.nz) 
Tim Cundy a (t.cundy@auckland.ac.nz) 
Alistair D Calder b (Alistair.Calder@gosh.nhs.uk) 
 
aDepartment of Medicine, University of Auckland, Private Bag 92019, Auckland 1142, New 
Zealand 
bGreat Ormond Street Hospital, Great Ormond Street, London WC1N 3JH, United Kingdom 
c University of East Anglia, Norwich, United Kingdom 
 
Address for correspondence:  
Dr Dorit Naot 
Department of Medicine 
University of Auckland, Private Bag 92019 
Auckland 1142, New Zealand 
Telephone: +64 9 923 86258 
Fax +64 9 373 7677 
















 Most cases of Juvenile Paget’s disease result from homozygous mutations in the 
gene TNFRSF11B.  
 In a boy with recurrent clavicular fractures, but an otherwise mild skeletal 
phenotype, we identified novel heterozygous mutations in TNFRSF11B.  
 Sequencing of parental DNA confirmed a compound heterozygous genotype, with 
one mutation maternally inherited and the other paternally inherited 
 
Abstract 
Juvenile Paget’s disease (JPD) is a rare recessively-inherited bone dysplasia.  The great 
majority of cases described to date have had homozygous mutations in TNFRSF11B, the gene 
encoding osteoprotegerin.  We describe a boy who presented with recurrent clavicular fractures 
following minor trauma (8 fractures from age 2 to 11). He was of normal height and despite 
mild lateral bowing of the thighs and anterior bowing of the shins he remained physically 
active.  Abnormal modelling was noted in ribs and humeri on clavicular radiographs, and a 
skeletal survey at the age of 7 showed generalised diaphyseal expansion of the long bones with 
thickening of the periosteal and endosteal surfaces of the cortices.  On biochemical evaluation, 
serum alkaline phosphatase was noted to be persistently elevated.  The diagnosis of JPD was 
confirmed by the finding of compound heterozygous mutations in TNFRSF11B: a maternally-
inherited A>G missense mutation at position 1 of the first amino acid codon (previously 
reported) and a paternally-inherited splice acceptor site mutation in intron 3 at a highly 
conserved position (not previously reported).  Bioinformatics analysis suggested both 
mutations were disease-causing.  Compound heterozygote mutations in TNFRSF11B causing 











phenotype.  The milder features may lead to delay in diagnosis and diagnostic confusion with 
other entities, but the extraskeletal features of JPD may nonetheless develop. 
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1.  Introduction 
Juvenile Paget’s disease (JPD; MIM #239000) is a rare, autosomal recessively-inherited 
disorder first described in 1956 [1].  Skeletal manifestations appear first in its natural history, 
with a characteristic generalised increase in bone turnover that leads to bone expansion, 
progressive bone deformity, and increased risk of low-energy fracture [2].  The severity of the 
skeletal phenotype disease varies, and Chong et al. have proposed a classification of severity 
based on the age at which symptoms first develop, the degree of skeletal deformity and the 
effects on mobility and growth [3].  Extra-skeletal manifestations appear in late childhood and 
adolescence and include hearing loss (due to skull involvement), a distinctive retinal dystrophy, 
calcification of the pinna, vascular calcification and internal carotid artery aneurysms [2, 4, 5].   
JPD is most commonly caused by bi-allelic inactivating mutations in the TNFRSF11B gene [2, 
6], although one subject with an activating mutation in TNFRSF11A and a JPD-like phenotype 
has been described [7].   TNFRSF11B encodes osteoprotegerin (OPG), a key regulator of 
osteoclastogenesis.  Binding of receptor activator of nuclear factor kappa B (RANK), which is 
expressed in immature osteoclasts, to RANK-ligand (RANKL), which is expressed by 
osteoblasts, is central to driving osteoclastogenesis;  OPG acts as a soluble decoy receptor that 
binds to RANKL and prevents its interaction with RANK, thus acting as a brake on 
osteoclastogenesis [8].  Inactivating mutations in OPG cause upregulation of bone resorption 
with a secondary increase in bone formation, resulting in the marked elevation of serum 










Approximately 80 cases of JPD have been reported in the literature.   A total of 13 different 
TNFRSF11B mutations have been identified to date - with the great majority having 
homozygous mutations, occurring either where a ‘bottleneck’ in population growth has 
occurred or consanguineous marriage is practiced [2].   To our knowledge there has been only 
one person with JPD identified as having compound heterozygous mutations, and his skeletal 
phenotype was at the milder end of the disease spectrum [9-12].   We describe here a further 
patient with a relatively mild skeletal phenotype, who was found to have compound 
heterozygous mutations in TNFRSF11B.    
 
2.  Materials and Methods 
2.1 Clinical Report  
The proband is an 11-year-old boy, one of two children born to healthy unrelated parents of 
normal stature.  His father had a history of surgery to the right humerus at 11 years of age for 
a bone cyst, and a single sport-related fracture of his right upper fibula, but there was no other 
family history of note.  The proband was born normally at term following an uneventful 
pregnancy.  He weighed 3.47kg and had no neonatal problems.  He passed his newborn hearing 
screen and his developmental milestones were normal.  He was first referred at 7 years of age 
having had five clavicular fractures involving both clavicles on different occasions, at 2, 4, 6 
and twice at 7 years of age.  Each time the fracture had occurred following a fall onto an 
outstretched arm.   
Otherwise he was in good general health, physically active and achieving well in a mainstream 
school.   He reported no pain other than that directly related to his fractures.  At 7.8 years of 
age he had a height of 124.9cm (25-50th centile) with a span:height ratio of 1.02 and a normal 











(upper:lower segment ratio 0.89; about 2 SD below normal for this age), with a barrel-shaped 
chest, loss of the normal lumbar lordosis, long slim legs with bowing of both femora and, to a 
lesser extent, the tibiae.  His hands, feet and joints appeared normal.  Dental examination was 
normal other than some discrete white patches involving the enamel on a few of the permanent 
teeth, but the enamel surface was intact.   Ophthalmology assessment at the age of 10y11mo 
found mild myopia, with normal anterior poles, lenses and retinae.  
At presentation his calcium, phosphate, renal and liver function, PTH, and 25-hydroxy vitamin 
D were all normal but his alkaline phosphatase was raised at 1192 U/L (normal range for boys 
age 8-9; 150-350 U/L).  Alkaline phosphatase electrophoresis showed two isoenzyme fractions, 
initially interpreted as being consistent with transient hyperphosphatasaemia of infancy and 
childhood. His urinary N-terminal telopeptide excretion (NTx) was high at 4580 nM/mM 
creatinine (upper limit of normal in children < 16 years is 325 nmol/mmol creatinine).  
Audiology assessment showed normal ear canals and tympanic membranes and tympanometry, 
absent oto-acoustic emissions bilaterally and bilateral high frequency hearing loss with notches 
on the pure tone audiograms at 4000 kHz down to 35dB on the right and 40 dB on the left.  His 
raised alkaline phosphatase and urinary NTx have all persisted at similar levels while his urea, 
electrolytes, calcium, phosphate, magnesium, liver function tests, thyroid function, PTH, IGF1 
and IGFBP-3 have all been normal.  Between the ages of 7 and 11 he sustained three further 
clavicular fractures but was otherwise well.   On assessment at age 11.7 he remained fully 
mobile and enjoying sport including cycling and football.  He had minimal deformity with mild 
femoral and tibial bowing and a barrel chest.   His growth remains normal (height 139.1 cm; 
25-50th centile). 
On initial assessment the possibility of mild Camurati-Engelmann syndrome was considered 
based on his body habitus and radiology.  However, molecular genetic panel testing on a 21 











were:  ANKH, CA2, CLCN7, CTSK, FAM123B, FAM20C, FERMT3, IKBKG, LEMD3, LRP5, 
OSTM1, SNX10, SOST, TCIRG1, PLEKHM1, PTH1R, RASGRP2, TNFRSF11A (RANK), 
TNFSF11 (RANKL) and TYROBP.  The possibility of atypical osteogenesis imperfecta was 
also considered but molecular genetic screening of COL1A1 and COL1A2 showed no 
pathogenic changes.   
2.2 Mutation analysis 
Genomic DNA was extracted from leukocytes using standard laboratory procedures.  PCR 
primers used were designed to amplify the five exons, including the intron/exon boundaries, of 
TNFRSF11B (Gene ID 4982, mRNA accession NM_002546.4) [13].  One additional primer 
was designed and used as the forward primer for amplification of exon 2, as it permitted clearer 
reading of the intron1-exon2 boundary.  The sequence of this primer was 5’-
CACTGCTATCTGCATTCCTGG.  PCR amplification was carried out by HOT FIREPol® 
DNA Polymerase (Solis BioDyne, Tartu, Estonia).  Following amplification, DNA fragments 
were separated by electrophoresis on 1% agarose gels, bands were purified from the gels by 
High pure PCR product purification kit (Roche) and submitted for direct Sanger sequencing on 
a 3130XL Genetic Analyzer (Life Technologies).   
2.3 Serum RANKL and OPG measurements 
Serum concentrations of soluble RANKL (sRANKL) and OPG were measured in the proband 
and both his parents using a sandwich enzyme-linked immunosorbent assay (ELISA) 
(Biomedica Medizinprodukte GmbH, Vienna, Austria). Intra- and inter-assay precision were 
≤10% for both assays. Limit of detections were 0.14 pmol/L and 0.01 pmol/L for OPG and 
sRANKL respectively. Normal interquartile ranges for these assays were taken from the paper 











The parents were closely involved in the decision to discuss the clinical features in an 
international expert forum and following that, to send the samples for research-based testing. 
 
3.  Results 
3.1 Radiological findings 
Radiographs obtained of the left shoulder at presentation with clavicular fractures aged 3 and 
5 revealed a diffuse sclerotic appearance with thickening of the humeral cortex (Figure 1).  
There was no hypoplasia of the clavicles.  A skeletal survey at age 7 showed widespread 
diaphyseal expansion of the long bones with cortical thickening and some endosteal thickening 
(Figure 2).  The hands were spared, and the spine and pelvis appeared normal.  There was mild 
thickening of the cranial vault, confirmed on a cranial CT performed one year later (Figure 3).  
The CT scan also showed areas of bilateral otic capsule demineralisation.  Bone density was 
evaluated by DXA (GE Lunar Prodigy Advance, Software: enCORE v14.1) at aged 9: the 













Figure 1.   Radiograph of left shoulder at aged 5.  There is a left clavicle fracture (arrow).  
Cortical thickening in the humerus is present (arrowheads) 
 
Figure 2.   Skeletal survey at aged 7.  a) Chest radiograph showing thickening of the central 
poritions of the ribs (arrows) and clavicles (arrowheads).  b) Pelvic radiograph shows normal 
pelvic bones; there is thickening of the femoral diaphyseal cortex involving both the cortical 
(arrow) and endosteal (arrowheads) surfaces.  Radiographs of right femur (c) and tibia (d) show 













Figure 3.  Cranial CT at aged 8. Coronal (a) and axial (b) reformats showing generalised mild 













3.2 Genetic analysis 
Sequence analysis of the five exons and flanking regions of TNFRSF11B in the patient’s DNA 
identified no homozygous mutations.  However, heterozygosity was found in two critical loci: 
c.1A>G in position 1 of the first amino acid codon of OPG, and c.592-2A>G in the splice 
acceptor site in intron 3 (Figure 4).   The c.1A>G initiation codon variant produces a missense 
mutation p.M1V, and has been previously documented as SNP rs1461751500 in position 
chr8:118951821, with an unknown frequency (NCBI dbSNP).  The second variation identified 
in intron 3, position chr8:118926720, has not been reported previously.   
Parental DNA was obtained for segregation analysis.  As shown in Figure 4, the mother was 
heterozygous for the mutation A>G in exon 1, and the father was heterozygous for the A>G 
splice acceptor site mutation in intron 3.  In addition, both parents are heterozygous for the 
variant c.C9G (p.N3K) at the third amino acid of OPG, which is a documented benign SNP 













Figure 4.   Mutation and segregation analyses of TNFRSF11B.  (A) DNA sequence of the 
region in exon 1 that includes the OPG start codon (underlined).  The child and mother are 
heterozygous A/G in position 1 of the first amino acid, while the father is homozygous for the 
wild type A allele.  Both parents are heterozygous C/G in position 3 of the third amino acid (a 
benign SNP).  The child is homozygous C in this position. (B) DNA sequence of intron 3/ exon 
4 boundary region.  The boundary is indicated by the black vertical line.  The second to last 
position in the intron is heterozygous G/A in the child and the father, while the mother is 
homozygous for the wild type A allele.  All the sequences have been confirmed on the 
complementary strands.   
Blue arrow- heterozygous loci; white arrow- homozygous, wild type loci; arrow heads-   
heterozygous loci of the known benign SNP.   
 

















3.3 Serum concentrations of OPG and sRANKL  
Immunoreactive OPG and sRANKL were detectable in the proband and both his parents.  OPG 
concentrations were low in both the proband and his father, and sRANKL concentrations 
elevated in all three.  The ratio of sRANKL to OPG, an index of the driving force to 
osteoclastogenesis, was high in both the father and the proband, but particularly so in the latter 
(Table 1). 
Table 1 



























0.2 0.69 0.29 
IQR – interquartile range using this assay [14]. 
 
4.  Discussion   
At presentation the diagnosis of this child’s bone disease, characterised by recurrent clavicular 
fractures, mild deformity of the lower limbs with diaphyseal expansion and cranial hyperostosis 
was not clear.  The high alkaline phosphatase levels did raise the possibility of juvenile Paget 
disease, but this was at first considered unlikely given the absence of pain, normal stature and 
near normal phenotype.  Radiography in typical cases of JPD shows enlarged bones with thick 
cortices, fractures and bowing of long bones, kyphosis, scoliosis, acetabular protrusion and 
severe hyperostosis of the skull (commonly leading to deafness), and in our patient these 











Clavicular fractures are common in young children but repeated fractures, such as this boy 
sustained, are unusual.   The radiological appearances raised several other possibilities.  These 
included Camurati-Engelmann disease (CED) which is characterised radiologically by 
diaphyseal bone expansion with both cortical and endosteal bone proliferation, sparing the 
epiphyses and metaphyses [15] – all features that were present in this case.  The lack of 
involvement in the hands and spine is also seen in CED, but children this age with CED 
typically present with bone pain and limb girdle weakness, and recurrent fractures are not a 
feature.  However, it is possible that mild juvenile Paget’s may be responsible for some cases 
previously labelled as CED in whom mutation testing for TGFB1 is negative.  
Given the presentation with fractures, other bone fragility states with bone modelling 
abnormalities were also entertained.  A rare high bone mass form of osteogenesis imperfecta, 
due to mutations at the C-propeptide cleavage site, has recently been elucidated [16].  This may 
present with abnormal bone modelling with diaphyseal expansion, particularly of the short 
tubular bones.  Despite recurrent fractures, spinal bone density is usually elevated.   However, 
in this case, spinal bone density was low and there were no mutations in COL1A1 or COL1A2. 
We also considered Pyle disease, a rare disorder due to mutations in SFRP4, which may 
manifest osteopenia and bone fragility [17].  Pyle disease exhibits marked metaphyseal 
undermodelling rather than expansion of the diaphyses, thus distinguishing it from juvenile 
Paget’s disease.  Cleinocranial dysplasia due to RUNX2 mutations is characterised by 
hypoplasia of the clavicles, but not fractures, and our patient had none of the other clinical 
features of this syndrome [18].  Gnathodiaphyseal dysplasia is a rare disorder caused by 
heterozygous mutation in the ANO5.  Bone fragility with recurrent fractures, high bone 
turnover and bowing and sclerosis of tubular bones are features of this condition, but our patient 











Mutation analysis of DNA from the child determined heterozygous variations in two critical 
loci of the TNFRSF11B gene: in the first amino acid codon and in the acceptor splice site of 
intron 3.   Analysis of DNA from the parents revealed that one mutation was inherited from 
each, establishing that the affected child had no wild type copy of TNFRSF11B.  The phenotype 
was mild as judged by the criteria suggested by Chong et al [3] with deformity recognised after 
2 years of age, normal mobility and normal growth.    
To our knowledge there has been only one previously reported case of a patient with JPD with 
compound heterozygous mutations in TNFRSF11B.   This patient was described in a number 
of earlier clinical papers: by the age of 5-years he had sustained eight fractures, but remained 
mobile and was of normal stature [9], thus the skeletal phenotype was mild.  However, the 
extraskeletal features were not benign; by the age of 10 he had developed cutaneous changes 
of pseudoxanthoma elasticum and retinal angioid streaks.   The retinal disease progressed over 
the next 11 years with sub-retinal haemorrhages causing significant visual impairment [11].  In 
an abstract published in 2003 he was shown to have a 3-base pair deletion in exon 2 and a 
nonsense mutation in exon 4 of TNFRSF11B [12].    Similarly, individuals with who are 
homozygous for the so-called Balkan mutation in TNFRSF11B (966_969delTGACinsCTT) 
also have a relatively mild skeletal phenotype, but severe retinal disease may develop with age 
[20]. 
To date, thirteen TNFRSF11B mutations that had been described in JPD patients.    The severity 
of the phenotype is related to the nature of the mutation.  Severe phenotypes (defined as 
deformity recognised by age 18 months, independent walking not maintained past the age of 5 
years, and height <3rd centile) are seen in patients with large deletions in TNFRSF11B or 











Using the bioinformatics software MutationTaster [21] to evaluate the pathogenic potential of 
the DNA sequence alterations identified here, each of these mutations was predicted to cause 
major disruptions of the expression and function of OPG.  The phenotypes of JPD patients 
carrying TNFRSF11B mutations previously described in the literature also support the view 
that mutations in these two sites are detrimental.  A homozygous mutation in the second 
position of the start codon c.2A>G (p.1M>R) was reported by Grasemann et al  in a patient 
with a severe JPD phenotype [22].  That patient was diagnosed in early infancy with 
demineralised, broadened bones with a coarse trabecular pattern, and severe coxa vara with 
shepherd’s crook deformity of the proximal femur and serum OPG serum levels were below 
the assay detection limit.  The novel mutation in the acceptor site junction of intron 3 is in 
position (-2), a highly conserved and nearly invariant position according to a comprehensive 
in silico analysis of human splice sites [23].  A homozygous splice site mutation causing a 20bp 
deletion in the donor site of exon 3 was described by Chong et al [3].  That patient also 
presented in infancy with a severe phenotype, with deformity that limited the development of 
walking.  Similar to the mutation found in the new case we describe, this deletion was predicted 
to cause a failure in the splicing of exons 3 and 4, and loss of function of OPG.   
Given that both mutations we identified are potentially associated with severe phenotypes, it is 
perhaps surprising that the skeletal phenotype is mild.  Our data do not provide a clear answer 
to this.  It is possible that as a consequence of the splice site mutation, alternative spicing may 
have produced a mutant OPG protein with retained activity, but this remains speculative.  This 
issue could perhaps be addressed by using the proband’s mRNA to determine the outcome of 
the splice site mutation. The proband had low but detectable serum concentrations OPG though 
it should be borne in mind that the assay detects fragments of OPG, monomeric and dimeric 
OPG as well as OPG/RANKL complexes. Circulating sRANKL levels were higher than normal 











proband’s sRANKL/OPG ratio was clearly elevated, suggesting there was a powerful drive to 
osteoclastic activity.  His mother’s OPG and sRANKL measurements were normal, but his 
father (who had the splice site mutation) had a relatively low OPG level and high 
sRANKL/OPG ratio.  
Bisphosphonates have been used in several children with JPD and it seems probable that 
skeletal deformity can be ameliorated by suppressing the greatly accelerated bone turnover 
during growth [24], but there is no evidence that it prevents the vascular and ocular 
complications.  In theory, denosumab, a RANK-ligand antibody, might be more effective, but 
to date only short term studies of its use have been reported [22, 25].   
 
Declarations of interest: none 
 
Acknowledgements 
This study was partially funded by the Health Research Council of New Zealand (Grant 
15/576).  We wish to thank Professor William Fraser for his assistance with laboratory 













1. Bakwin H, Eiger MS (1956) Fragile bones and macrocranium. J Pediatr 49:558-564 
2. Polyzos SA, Cundy T, Mantzoros CS (2018) Juvenile Paget disease. Metabolism 80:15-
26 
3. Chong B, Hegde M, Fawkner M, Simonet S, Cassinelli H, Coker M, Kanis J, Seidel J, 
Tau C, Tuysuz B, Yuksel B, Love D, Cundy T (2003) Idiopathic hyperphosphatasia 
and TNFRSF11B mutations: relationships between phenotype and genotype. J Bone 
Miner Res 18:2095-2104 
4. Gottesman GS, Madson KL, McAlister WH, Nenninger A, Wenkert D, Mumm S, 
Whyte MP (2016) Auricular ossification: A newly recognized feature of 
osteoprotegerin-deficiency juvenile Paget disease. Am J Med Genet A 170A:978-985 
5. Kerr NM, Cassinelli HR, DiMeglio LA, Tau C, Tuysuz B, Cundy T, Vincent AL (2010) 
Ocular manifestations of juvenile Paget disease. Arch Ophthalmol 128:698-703 
6.         Whyte MP, Obrecht SE, Finnegan PM, Jones JL, Podgornik MN, McAlister WH, 
Mumm S. Osteoprotegerin deficiency and juvenile Paget's disease. N Eng J Med 
2002;347:175-84 
7. Whyte MP, Tau C, McAlister WH, Zhang X, Novack DV, Preliasco V, Santini-Araujo 
E, Mumm S (2014) Juvenile Paget's disease with heterozygous duplication within 
TNFRSF11A encoding RANK. Bone 68:153-161 
8. Boyle JW, Simonet S, Lacey DL (2003) Osteoclast differentiation and activation. 
Nature 423:337-342 
9. Woodhouse NJ, Fisher MT, Sigurdsson G, Joplin GF, MacIntyre I (1972) Paget's 
disease in a 5-year-old: acute response to human calcitonin. Br Med J 4:267-269 
10. Doyle FH, Woodhouse NJ, Glen AC, Joplin GF, MacIntyre I (1974) Healing of the 











11. Sharif KW, Doig WM, Kinsella FP (1989) Visual impairment in a case of juvenile 
Paget's disease with pseudoxanthoma elasticum: an eleven year follow up. J Pediatr 
Ophthalmol Strabismus 26:299-302 
12. Mumm S, Banze S, Pettifor J, Tau C, Schmitt K, Ahmed A, Whyte MP (2003) Juvenile 
Paget's disease: molecular analysis of TNFRSF11B encoding osteoprotegerin indicates 
homozygous deactivating mutations from consanguinity as the predominant etiology. 
In: ASBMR 2003 Annual Meeting. J Bone Miner Res, 18; S373, (Minneapolis, 
Minnesota, USA) 
13. Naot D, Choi A, Musson DS, Simsek Kiper PO, Utine GE, Boduroglu K, Peacock M, 
DiMeglio LA, Cundy T (2014) Novel homozygous mutations in the osteoprotegerin 
gene TNFRSF11B in two unrelated patients with juvenile Paget's disease. Bone 68:6-
10 
14.        Ali SA, Kang H, Olney R, Ramos-Platt L, Ryabets-Lienhard A, Georgia S, 
Pitukcheewanont P (2019).  Quantifying RANKL and OPG levels in healthy children: 
a large cross-sectional analysis. Bone 127: 215-219. 
15. Janssens K, Vanhoenacker F, Bonduelle M, Verbruggen L, Van Maldergem L, Ralston 
S, Guanabens N, Migone N, Wientroub S, Divizia MT, Bergmann C, Bennett C, Simsek 
S, Melancon S, Cundy T, Van Hul W (2006) Camurati-Engelmann disease: review of 
the clinical, radiological, and molecular data of 24 families and implications for 
diagnosis and treatment. J Med Genet 43:1-11 
16. Cundy T, Dray M, Delahunt J, Hald JD, Langdahl B, Li C, Szybowska M, Mohammed 
S, Duncan EL, McInerney-Leo AM, Wheeler PG, Roschger P, Klaushofer K, Rai J, 
Weis M, Eyre D, Schwarze U, Byers PH (2018) Mutations that alter the carboxy-
terminal-propeptide cleavage site of the chains of type I procollagen are associated with 











17. Kiper POS, Saito H, Gori F, Unger S, Hesse E, Yamana K, Kiviranta R, Solban N, Liu 
J, Brommage R, Boduroglu K, Bonafe L, Campos-Xavier B, Dikoglu E, Eastell R, 
Gossiel F, Harshman K, Nishimura G, Girisha KM, Stevenson BJ, Takita H, Rivolta C, 
Superti-Furga A, Baron R (2016) Cortical-bone fragility--insights from sFRP4 
deficiency in Pyle's disease. N Engl J Med 374:2553-2562 
18.       Mundlos S.  Cleidocranial dysplasia: clinical and molecular genetics.  J Med Genet 
1999; 36: 177-182. 
19.        Rolvien T, Koehne T, Kornak U, Lehmann W, Amling M, Schinke T, Oheim R. A novel 
ANO5 mutation causing gnathodiaphyseal dysplasia with high bone turnover 
osteosclerosis. J Bone Miner Res. 2017;32:277-284. 
20. Whyte MP, Singhellakis PN, Petersen MB, Davies M, Totty WG, Mumm S (2007) 
Juvenile Paget's disease: the second reported, oldest patient is homozygous for the 
TNFRSF11B "Balkan" mutation (966_969delTGACinsCTT), which elevates 
circulating immunoreactive osteoprotegerin levels. J Bone Miner Res 22:938-946 
21. Schwarz JM, Cooper DN, Schuelke M, Seelow D (2014) MutationTaster2: mutation 
prediction for the deep-sequencing age. Nat Methods 11:361-362 
22. Grasemann C, Schundeln MM, Hovel M, Schweiger B, Bergmann C, Herrmann R, 
Wieczorek D, Zabel B, Wieland R, Hauffa BP (2013) Effects of RANK-ligand antibody 
(denosumab) treatment on bone turnover markers in a girl with juvenile Paget's disease. 
J Clin Endocrinol Metab 98:3121-3126 
23.       Ma SL, Vega-Warner V, Gillies C, Sampson MG, Kher V, Sethi SK, Otto EA (2015) 
Whole exome sequencing reveals novel PHEX splice site mutations in patients with 
hypophosphatemic rickets. PLoS One 10:e0130729 
24. Cundy T, Wheadon L, King A (2004) Treatment of idiopathic hyperphosphatasia with 










25. Polyzos SA, Singhellakis PN, Naot D, Adamidou F, Malandrinou FC, Anastasilakis 
AD, Polymerou V, Kita M (2014) Denosumab treatment for juvenile Paget's disease: 
results from two adult patients with osteoprotegerin deficiency ("Balkan" mutation in 
the TNFRSF11B gene). J Clin Endocrinol Metab 99:703-707 
 
 
Jo
ur
na
l P
re
-p
ro
of
